全文获取类型
收费全文 | 546篇 |
免费 | 18篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 52篇 |
妇产科学 | 4篇 |
基础医学 | 61篇 |
口腔科学 | 12篇 |
临床医学 | 60篇 |
内科学 | 109篇 |
皮肤病学 | 8篇 |
神经病学 | 9篇 |
特种医学 | 148篇 |
外科学 | 19篇 |
综合类 | 5篇 |
预防医学 | 22篇 |
眼科学 | 3篇 |
药学 | 26篇 |
肿瘤学 | 27篇 |
出版年
2024年 | 1篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 8篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 5篇 |
2014年 | 12篇 |
2013年 | 19篇 |
2012年 | 5篇 |
2011年 | 11篇 |
2010年 | 26篇 |
2009年 | 18篇 |
2008年 | 11篇 |
2007年 | 8篇 |
2006年 | 8篇 |
2005年 | 13篇 |
2004年 | 7篇 |
2003年 | 12篇 |
2002年 | 5篇 |
2001年 | 13篇 |
2000年 | 10篇 |
1999年 | 10篇 |
1998年 | 33篇 |
1997年 | 27篇 |
1996年 | 25篇 |
1995年 | 26篇 |
1994年 | 26篇 |
1993年 | 19篇 |
1992年 | 7篇 |
1991年 | 7篇 |
1990年 | 12篇 |
1989年 | 17篇 |
1988年 | 18篇 |
1987年 | 14篇 |
1986年 | 9篇 |
1985年 | 17篇 |
1984年 | 8篇 |
1983年 | 9篇 |
1982年 | 20篇 |
1981年 | 12篇 |
1980年 | 10篇 |
1979年 | 1篇 |
1978年 | 4篇 |
1977年 | 8篇 |
1976年 | 14篇 |
1975年 | 8篇 |
1973年 | 1篇 |
排序方式: 共有565条查询结果,搜索用时 15 毫秒
91.
92.
Solid phase red cell adherence immunoassay for anti-HIV 1: a simple, rapid, and accurate method for donor screening 总被引:1,自引:0,他引:1
EJ Watson-Williams ; JL Yee ; JR Carlson ; SC Mertens ; P Holland ; L Sinor ; FV Plapp 《Transfusion》1988,28(2):184-186
In technically developed countries in which acquired immunodeficiency syndrome is a risk to the recipients of blood or tissue, it is mandatory to screen the donor for evidence of HIV (human immunodeficiency virus) infection. Current tests, based on enzyme-linked immunoassay, are time-consuming and expensive and as such are unsuitable for developing countries. We describe a second generation test using anti-human IgG coupled to red cells as the indicator of antibody having reacted with test antigen (1). The test is complete within ten minutes, simple to perform and to read and has 100% sensitivity and 99% specificity compared with Western blot. It is ideal for the rapid screening of organ donors and for the screening of blood donors where cost is a major consideration. 相似文献
93.
94.
95.
Ovarian metastases: computed tomographic appearances 总被引:4,自引:0,他引:4
Computed tomographic scans of 34 patients with ovarian metastases were reviewed to assess the radiographic appearances and to correlate these with the primary neoplasms. Primary neoplasms were located in the colon (20 patients), breast (six), stomach (five), small bowel (one), bladder (one), and Wilms tumor of the kidney (one). The radiographic appearance of the metastatic lesions could be described as predominantly cystic (14 lesions), mixed (12 lesions), or solid (seven lesions). There was one false-negative examination which showed no ovarian enlargement, although neoplastic deposits were found on the ovary at laparotomy. The cystic and mixed lesions tended to be larger in overall diameter than the solid. The metastases from gastric carcinoma appeared solid in four of five cases. The metastases from the other neoplasms had variable appearances simulating primary ovarian carcinoma. 相似文献
96.
97.
Transcatheter embolization of intrahepatic arterial aneurysms 总被引:3,自引:0,他引:3
98.
Constitutive expression of platelet glycoproteins by the human leukemia cell line K562 总被引:7,自引:0,他引:7
The human leukemia cell line K562 was derived from a patient with chronic granulocytic leukemia. This cell line has subsequently been shown to possess phenotypic markers typical of erythroid and myeloid cells. Using a rabbit antiserum directed against purified platelet glycoproteins (PGPs), we have obtained evidence for the constitutive expression of PGPs on the surface of K562 cells. PGPs expressed have been tentatively identified as IIa and III based on their apparent migration in a 7% sodium dodecylsulfate polyacrylamide gel. K562 may become an important tool for the study of early events involved in megakaryocytic differentiation. 相似文献
99.
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas 总被引:4,自引:0,他引:4
BACKGROUND: Inhibitor of apoptosis proteins (IAPs) inhibit apoptosis by binding specific caspases, and possibly by other mechanisms. Eight IAPs have been identified in humans, of which cIAP1, cIAP2, and XIAP are well known. IAPs are being investigated as potential treatment targets in cancer patients. METHODS: cIAP1, cIAP2, and XIAP were assessed in lymphoma cell lines, 240 B-cell non-Hodgkin lymphoma (NHL) tumors, and 40 Hodgkin lymphoma (HL) tumors. RESULTS: All IAPs were expressed in most NHL and all HL cell lines. In NHL tumors, cIAP1 was expressed in 174 (73%), cIAP2 in 115 (48%), and XIAP in 37 (15%). cIAP1 was positive in all precursor B-cell lymphoblastic lymphoma/leukemia (LBL) and nodal marginal zone B-cell lymphoma (MZL), over 90% of follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), and approximately 50% to 60% of myeloma, Burkitt lymphoma (BL), lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM), small lymphocytic lymphoma/ chronic lymphocytic leukemia (SLL/CLL), extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT-lymphoma), splenic MZL, and mantle cell lymphoma. cIAP2 was positive in all MALT-lymphoma, over 90% of precursor B-cell LBL (94%), most BL (75%), LPL/WM (71%), and SLL/CLL (67%), and approximately 40% to 60% of follicular lymphoma, myeloma, and DLBCL. XIAP was positive most cases of precursor B-cell LBL (57%) and approximately 30% to 40% of nodal MZL, BL, and DLBCL. In HL tumors, cIAP1 was positive in 30 (75%), cIAP2 in 27 (68%), and XIAP in 23 (58%), and did not correlate with histologic type. CONCLUSIONS: Differential expression of IAPs in B-cell lymphomas suggests differences in pathogenesis that may have implications for novel treatment strategies targeting IAPs. 相似文献
100.
Tsimberidou AM Catovsky D Schlette E O'Brien S Wierda WG Kantarjian H Garcia-Manero G Wen S Do KA Lerner S Keating MJ 《Cancer》2006,107(1):125-135
BACKGROUND: The optimal management of patients with splenic marginal zone lymphoma/marginal zone lymphoma (SMZL) is controversial. The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone. METHODS: The Leukemia Service database was searched for patients with splenic lymphoma who were registered between May 1995 and October 2004. The indications for treatment were the same as those used for patients with chronic lymphocytic leukemia. RESULTS: SMZL was confirmed in 70 patients. The median age was 64 years. The median number of CD20 molecules per cell was 69 x 10(3). Forty-three patients required systemic therapy; rituximab in 26 patients, chemotherapy plus rituximab in 6 patients, and chemotherapy alone in 11 patients. Ten additional patients underwent splenectomy, and 17 patients were in the observation group. The overall response rates were 88% with rituximab, 83% with rituximab plus chemotherapy, and 55% with chemotherapy alone; the 3-year survival rates were 95%, 100%, and 55%, respectively. The 3-year failure-free survival (FFS) rates were 86%, 100%, and 45% in the rituximab, rituximab plus chemotherapy, and chemotherapy alone groups, respectively. Rituximab treatments resulted in longer survival and FFS compared with chemotherapy. Rituximab alone resulted in disappearance of splenomegaly in 92% of patients and normalization of absolute lymphocyte counts. In univariate analysis, younger age and rituximab-based therapy were predictive of longer FFS. CONCLUSIONS: Rituximab with or without chemotherapy was found to have major activity in patients with SMZL. These results may be associated with high levels of cellular CD20 antigen sites. Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases. 相似文献